2025年6月16日，诗健生物与位于西班牙圣地亚哥-德孔波斯特拉的生物技术公司SunRock Biopharma宣布达成战略联盟，共同开发全球首创（First-in-Class）靶向C-C基序趋化因子受体9（CCR9）的抗体偶联药物（ADC）SRB123。CCR9是一种在胰腺癌、卵巢癌和肺癌等多种实体瘤中过表达的肿瘤相关抗原。

此次合作将SunRock专有的SRB1抗体与诗健生物的EZWi-Fit™联接子-载荷平台相结合，打造出一款专为CCR9高表达和高内化率实体瘤设计的高度差异化候选药物。SRB1抗体具有高亲和力和高效的肿瘤细胞内化能力，而EZWi-Fit™平台作为新一代ADC技术，其联接子稳定性和载荷在肿瘤组织中的选择性释放特性均经过优化。

根据协议，双方已于去年联合申请专利，并享有相互的许可选择权。合作的首要目标是获取扎实的临床前概念验证数据，以支持SRB123在短期内进入早期临床研究。

“我们在抗体工程方面的深厚专业知识与诗健生物创新的偶联平台相结合，有望开发出具有全球首创潜力的精准肿瘤治疗候选药物。”SunRock首席执行官Laureano Simón博士表示，“CCR9作为尚未充分开发但经临床验证的靶点，该项目旨在为预后较差的侵袭性肿瘤患者解决未满足的临床需求。”

诗健生物联合创始人兼首席执行官周清博士表示：“此次与SunRock的战略合作，不仅与我们致力于通过技术创新开发全球首创精准肿瘤治疗候选药物的愿景相契合，也进一步证明了EZWi-Fit™平台在新一代ADC开发中的独特优势。该平台以其卓越的抗肿瘤活性和良好的耐受性，为靶向CCR9高表达实体瘤的创新疗法提供了坚实基础。我们相信，强强联合将加速SRB123的研发进程，为患者带来新的希望。”

CCR9与肿瘤转移潜力和化疗耐药性密切相关，尤其在胰腺癌和卵巢癌中表现突出。SunRock的裸抗SRB1已在这些模型中展现出优异的临床前疗效。而ADC形式的SRB123在保留靶向能力的同时，结合诗健生物的载荷递送系统进一步增强了对肿瘤细胞的杀伤作用。

该合作伙伴关系将在2025年 BIO International Convention上展示，届时双方将与潜在的开发和商业化合作伙伴展开交流。

关于SunRock Biopharma

SunRock Biopharma是一家专注于开发下一代抗体疗法的生物技术公司，致力于满足肿瘤学和免疫学领域未满足的医疗需求。公司采用开放创新模式，结合前沿学术科学、先进技术平台和选择性商业策略，开发高度差异化的可授权资产。其产品组合包括优化的单克隆抗体、下一代ADC和放射性偶联物，靶点包括CCR9和HER3等。SunRock采用早期对外授权策略，旨在最大化风险调整后的回报，并与全球领先的制药和生物技术合作伙伴保持积极合作。

关于诗健生物

诗健是一家位于中国上海的临床阶段生物技术公司，聚焦创新ADC药物的开发。目前诗健最前端的Trop-2 ADC管线ESG401已进入三期临床试验。诗健新一代联接子-载荷技术平台EZWi-Fit®，在安全性、有效性、抗耐药性和药代动力学特征方面都具有显著的竞争优势。借助这一平台技术，诗健正在快速拓展针对新靶点或已验证靶点的ADC产品线，首款搭载EZWi-Fit®技术的 ADC 产品已成功启动首个人体临床试验。诗健也已经成功将此平台技术授权给国内和国际多家生物技术公司，赋能其创新ADC项目。

Escugen and SunRock Biopharma Forge Alliance to Develop First-in-Class CCR9-Targeted ADC

Shanghai, China, and Santiago de Compostela, Spain. June 16, 2025.

Escugen and SunRock Biopharma and have joined forces in a strategic partnership to co-develop SRB123 a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer.

The collaboration combines SunRock’s proprietary SRB1 antibody, selected for its high binding affinity and efficient tumor cell internalization, with Escugen’s EZWi-Fit™ linker-payload platform, a next-generation ADC technology optimized for the linker stability and selective tumor release of the potent payload. The result is a highly differentiated therapeutic candidate designed exclusively for solid tumors with high CCR9 expression and internalization rates.

Under the agreement, both companies will share development responsibilities, file joint patents, and hold reciprocal licensing option rights. The primary goal is to generate robust preclinical proof-of-concept data to support early clinical entry in the near term.

“Combining our deep antibody engineering expertise with Escugen’s innovative conjugation platform enables us to deliver a precision oncology candidate with First-in-Class potential,” said Dr. Laureano Simón, CEO of SunRock. “CCR9 remains an underexploited but clinically validated target. This program addresses real unmet needs in aggressive tumors with poor prognosis.”

Dr. Qing Zhou, Co-Founder and CEO of Escugen, stated, “This strategic collaboration with SunRock Biopharma aligns with our vision of developing First-in-Class precision oncology candidates through technological innovation. It further highlights the unique advantages of our EZWi-Fit™ platform technology in next-generation ADC development. The platform’s strong anti-tumor activity and favorable tolerability provide a solid foundation for targeting high CCR9-expressing solid tumors. We are confident that combining our expertise will accelerate SRB123’s progress and bring new hope to patients.”

CCR9 has been associated with metastatic potential and chemoresistance, particularly in pancreatic and ovarian cancers. SRB1, the unconjugated antibody from SunRock, has already demonstrated strong preclinical efficacy in these models. The ADC format (SRB123) leverages this targeting while enhancing tumor cell killing via Escugen’s payload delivery system.

The partnership will be showcased during the BIO International Convention 2025, where both companies will engage with potential development and commercialization partners.

About SunRock Biopharma

SunRock Biopharma is a biotech company focused on developing next-generation antibody-based therapies targeting unmet medical needs in oncology and immunology. Operating under an open innovation model, SunRock combines cutting-edge academic science, advanced technology platforms, and a selective business approach to generate highly differentiated, licensable assets. Its portfolio includes optimized monoclonal antibodies, next-generation ADCs, and radioconjugates, with validated targets such as CCR9 and HER3. SunRock follows an early-stage out-licensing strategy, designed to maximize risk-adjusted returns, and maintains active collaborations with leading pharma and biotech partners worldwide.

About Escugen

Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated target. The first ADC product baring the EZWi-Fit® technology has successfully launched its FIH clinical campaign. In addition, Escugen has licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.